The MTOPS Study: New Findings, New Insights, and Clinical Implications for the Management of BPH  Michael Marberger  European Urology Supplements  Volume 5, Issue 9, Pages 628-633 (June 2006) DOI: 10.1016/j.eursup.2006.05.002 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Cumulative incidence of progression of benign prostatic hyperplasia in the Medical Therapy of Prostate Symptoms (MTOPS) Study. Reproduced with permission from McConnell J et al. N Engl J Med 2003;349:2387–98. European Urology Supplements 2006 5, 628-633DOI: (10.1016/j.eursup.2006.05.002) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Cumulative incidence of acute urinary retention in men receiving finasteride, doxazosin, a combination of both, or placebo in the Medical Therapy of Prostate Symptoms (MTOPS) Study. Reproduced with permission from McConnell J et al. N Engl J Med 2003;349:2387–98. European Urology Supplements 2006 5, 628-633DOI: (10.1016/j.eursup.2006.05.002) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Change from baseline in prostate volume at 4 yr in the Medical Therapy of Prostate Symptoms (MTOPS) Study [7]. European Urology Supplements 2006 5, 628-633DOI: (10.1016/j.eursup.2006.05.002) Copyright © 2006 European Association of Urology Terms and Conditions